Subscribe To
Thomson reuters buys casetext, an ai legal tech startup, for $650m in cash
Thomson Reuters has entered into a definitive agreement to acquire Casetext, a Y Combinator-backed legal tech startup. The deal, valued at $650 millio...
June 26, 2023, 11:09 pm
Retinalgenix technologies, inc. nears completion of institutional review board for research on dna/gps program
Study Intends To Identify Hematology Biomarkers That May Help Personalize Medical Evaluations For Patie...
June 26, 2023, 10:15 am
The robomarkets weekly review and outlook – dax with sell signal – profit warnings and interest rate fears weigh on the market
This week, the DAX sent out a sell signal and initiated a trend reversal. The post The Robomarkets Week...
June 23, 2023, 11:42 am
Matrixport’s bitcoin greed & fear index surpasses 90%, suggests bull breather ahead
Bitcoin (BTC) has chalked up a more than 20% price gain since last Thursday. The exuberant rally may now take a cust...
June 23, 2023, 7:59 am
Uniqure (qure) falls on mixed huntington's disease study results
uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in...
June 22, 2023, 11:51 am
Gbp/usd forecast: gaining back to 1.28 ahead of boe meeting
Fed Chair Powell adhered to his customary messaging during his testimony. The BoE will likely raise int...
June 22, 2023, 8:35 am
Madrigal pharmaceuticals presents phase 3 maestro-nash data during the opening general session of the easl congress™
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroups Noninvasive...
June 22, 2023, 7:30 am
U.s. cannabis producer terrascend says it received ‘conditional approval' to list in toronto
TerrAscend Corp. TRSSF, -1.78%, a cannabis producer with operations in several U.S. states, said Wednesday that it had received “conditional approva...
June 21, 2023, 4:10 pm
Nurix therapeutics presents data from studies of its targeted protein degraders in b cell malignancies and initiates expansion of nx-2127 phase 1b trial in diffuse large b cell lymphoma and mantle cel
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete ...
June 14, 2023, 11:00 am
Aptamer surges on breakthrough in development of alzheimer's early diagnosis test
Aptamer Group PLC (AIM:APTA) shares surged over 200% higher in morning trade after the firm and Neuro-Bio, an Oxford-based biotech, announced a break...
June 14, 2023, 4:19 am
Palomar holdings (plmr) gains 31% ytd: more upside left?
Strong premium retention rates, new partnerships, rate increases and effective capital deployment continue to drive this Zacks Rank #3 (Hold) insurer....
June 12, 2023, 1:28 pm
Sera prognostics: buy the pretrm moat
Sera Prognostics is a promising company with a mission to improve pregnancy outcomes through its blood test product, PreTRM, which identifies bi...
June 8, 2023, 6:58 pm
Robomarkets wins “best stocks broker” award at global forex awards 2023 – b2b
Robomarkets is thrilled to announce that it was honoured with the prestigious “Best Stocks Broker” ...
June 7, 2023, 8:58 pm
Quanterix to participate in fireside chat at goldman sachs annual global healthcare conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive bi...
June 7, 2023, 4:00 pm
Intercept (icpt) announces positive data from pbc study
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple bi<...
June 7, 2023, 3:49 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor bi...
June 3, 2023, 1:00 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor bi...
June 3, 2023, 1:00 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor bi...
June 3, 2023, 1:00 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor bi...
June 3, 2023, 1:00 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor bi...
June 3, 2023, 1:00 pm